Good Monday Everyone... hope you all had a great weekend. I hope you’ve got your rally cap on because it appears the markets are very aware of Valentine’s tomorrow... there’s plenty of love in the air. The markets gapped up rotating more short sellers this morning with a vote of confidence for the bullish trend that continues to make new short-term highs with all of the major indices. However, the news pundits can only seem to attribute the move higher to Greece and now an underlying improvement in the Asian economies when in fact the real reason for the market’s strength is a bet that we’re improving the economic landscape here at home and investing in America is become the preferred global theme once again. The NASDAQ is in no man's land just ripping and leading all major indexes higher. I've noted in recent editions that the underlying strength of tech is the main foundation of the rally. Tech is leading the charge and it's my belief that will continue throughout the rest of the year. I don't see any other major sector of the market heating up quite like tech has and will likely continue to do so. That includes clean tech, computer tech, wireless tech, biotech and whatever any other kind of tech you can think of. Tech is where we want to be. The S&P and the DOW have been no slouches either. Although they are only testing their 52 week highs or slightly higher, that's still an impressive move nonetheless. If the economy proves to seriously be shaping up, we can expect those two indexes to catch up and move in line with the NASDAQ... but for now, risk is on and tech is it. If you're looking for some help trading the index options, buy the dips and sell the rips. It has been that simple. Easier said than done though if you're a little skeptical of this market's resilience of late... but as they've said for as long as the markets have been around, don't fight the tape. A Step in the Right Direction for Diabetes Research We initiated coverage last Monday on a small biotech, PositiveID Corp. (PSID), with some compelling technology that focuses on two very promising but different areas of research, terrorism threats and glucose monitoring research for diabetes, a growing problem faced by over 25 million Americans. The implications of the Company's technology is huge to say the least and if they can execute, continue to find positive test results and get their glucose monitoring technologies to market, longer-term investors should be heavily rewarded. If you'd like to get caught up to speed on what PSID has going on, peruse the PSID Stock HQ Hub at the site, there's plenty of very interesting reading there. It appears things are heating up for PositiveID on the research and development front which usually proves promising for stocks of this nature. One of the Company's two main divisions has been devoted to the critical topic of glucose monitoring. The Company has two very revolutionary glucose monitoring devices, one that tests your levels of glucose through your breath and the other through an implantable RFID microchip which measures your glucose levels in real-time. Both much more non-invasive than having to prick your finger and very much anticipated types of monitoring solutions for diabetics around the world. Last week, PSID announced that it has commenced a clinical trial of its Easy Check™ non-invasive breath glucose detection device for people with diabetes. The clinical trial, being held at Schneider Children's Medical Center in Israel, a preeminent research hospital, will initially focus on people with type 1 diabetes and the Company expects to begin recruiting subjects this month. Currently under development in Israel, Easy Check is a non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. We'll look to keep you updated on those trials in the coming months ahead. More importantly in my opinion, today, PSID announced positive preliminary results from its biotransport research study with the Diabetes Research Institute ("DRI") at the University of Miami relating to PositiveID's GlucoChip™. Like I mentioned above, GlucoChip is a glucose-sensing implantable microchip (currently under development with partner RECEPTORS LLC) for individuals with diabetes. Preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids. PositiveID's first animal studies were designed to test the membrane materials that will be the interface between the glucose sensing device and the in vivo environment by evaluating the ability of glucose to pass through the membrane to the sensing device (glucose transport). There's nothing better than watching stories like this positively unfold and being a part of it. New technology stocks are rewarded every day in the market and PSID is one of those stories with ground-breaking potential. If you're interested in listening to an audio interview of Chairman and CEO of PSID, William J. Caragol, here's a link to listen to the interview: http://smallcapvoice.com/blog/2-8-12-smallcapvoice-interview-with-positiveid-corporation-otcbb-psid/. Both announcements are most definitely a step in the right direction. I don't even need to go into the revenue implications should PositiveID get clinical approval on these products get them to market and in the hands of the right medical device or pharma partners. The potential is enormous. However, they are still in the very early stages of development which is why you can pick up the stock right now at around $.13 - $.14 cents. If you're willing to take a shot and allocate some risk capital to PSID, it's better to be in early than chasing it later. If PSID's stock can follow through on last week's volume interest and start making a move above the $.15 cent level, this one could also become a very good trader for speculative players to make some money with. Stay tuned. It's a great start to the week. Let's all continue to make some money. Back at ya' tomorrow.